Uric acid and oxidative stress—relationship with cardiovascular, metabolic, and renal impairment

ME Gherghina, I Peride, M Tiglis, TP Neagu… - International Journal of …, 2022 - mdpi.com
Background: The connection between uric acid (UA) and renal impairment is well known
due to the urate capacity to precipitate within the tubules or extra-renal system. Emerging …

Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection

JT Kielstein, R Pontremoli, M Burnier - Current Hypertension Reports, 2020 - Springer
Abstract Purpose of Review In chronic kidney disease (CKD), plasma uric acid levels are
increased because of the decrease in glomerular filtration rate. However, in addition to CKD …

Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy

TH Lee, JJ Chen, CY Wu, CW Yang, HY Yang - Diagnostics, 2021 - mdpi.com
The relationship between hyperuricemia, gout, and renal disease has been investigated for
several years. From the beginning, kidney disease has been considered a complication of …

Renal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation

GY Tang, S Li, Y Xu, C Zhang, XY Xu, L Xu, N Wang… - Phytomedicine, 2023 - Elsevier
Background Hyperuricemic nephropathy may be induced by the elevation and accumulation
of uric acid in kidney after hyperuricemia, which leads to kidney residential cells apoptosis …

Review of urate-lowering therapeutics: from the past to the future

C Jenkins, JH Hwang, JB Kopp, CA Winkler… - Frontiers in …, 2022 - frontiersin.org
We reviewed all currently available ULT, as well as any medications in development using
following databases: United States Food and Drug Administration (FDA), European …

[HTML][HTML] Hyperuricemia and chronic kidney disease: to treat or not to treat

F Piani, F Sasai, P Bjornstad, C Borghi… - Brazilian Journal of …, 2021 - SciELO Brasil
Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of
patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular …

The Terminalia chebula Retz extract treats hyperuricemic nephropathy by inhibiting TLR4/MyD88/NF-κB axis

H Liu, Z Chen, M Liu, E Li, J Shen, J Wang… - Journal of …, 2024 - Elsevier
Ethnopharmacological relevance Hyperuricemic nephropathy (HN) is a renal injury caused
by hyperuricemia and is the main cause of chronic kidney disease and end-stage renal …

A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular …

H Yanai, H Adachi, M Hakoshima, S Iida, H Katsuyama - Cells, 2024 - mdpi.com
The reabsorption of uric acid (UA) is mainly mediated by urate transporter 1 (URAT1) and
glucose transporter 9 (GLUT9) in the kidneys. Dotinurad inhibits URAT1 but does not inhibit …

[PDF][PDF] Эффективность фебуксостата у пациентов с подагрой в зависимости от функции почек

МС Елисеев, ОВ Желябина, МН Чикина… - Русский …, 2022 - rusmedreview.com
РЕЗЮМЕ Цель исследования: определить вероятность достижения целевого уровня
мочевой кислоты (МК) при проведении терапии фебуксостатом в таблетированной …

GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study

M Ueda, K Fukui, N Kamatani, S Kamitsuji… - Journal of Human …, 2023 - nature.com
Although chronic kidney disease (CKD) is recognized as a major public health concern,
effective treatment strategies have yet to be developed. Identification and validation of drug …